NICE issues early 'no' votes on Roche's RoActemra, Novartis' Rydapt

6th December 2017 Uncategorised 0

Two Swiss pharma giants got some news out of England Tuesday that they weren’t too excited about. The National Institute for Health and Care Excellence shot down both Roche’s RoActemra, as a treatment for giant cell arteritis, and Novartis’ Rydapt, as a therapy for a specific type of acute myeloid leukemia, in draft guidance.

More: NICE issues early 'no' votes on Roche's RoActemra, Novartis' Rydapt
Source: fierce